SERPINB3 and metabolic dysfunction-associated steatotic liver disease: In addition, studies on transgenic mice, either overexpressing SerpinB3 or carrying Serpinb3 deletion, and in vitro studies on human macrophage cell lines have shown that SerpinB3 can operate as a pro-inflammatory mediator in two models of progressive non-alcoholic fatty liver disease (NAFLD) [13], a definition that has been recently replaced by the new definition of “metabolic dysfunction-associated steatotic liver disease” (MASLD) [14].